Abnormalities in renal tubular phosphate handling in children with sickle cell disease
- 17 August 2014
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (12) , 2267-2270
Abstract
Background: The mechanisms responsible for the hyperphosphatemia in patients with sickle cell disease (SCD) and preserved glomerular filtration rate (GFR) are not fully understood. The role of fibroblast growth factor 23 (FGF23), a phosphaturic hormone has not been investigated in SCD. Hence, we evaluated parameters of renal tubular phosphorus handling and their relation to prevailing FGF23 levels in a cohort of young SCD patients.Methods: Renal tubular phosphate handling and circulating levels of various analytes including FGF23 and parathyroid hormone (PTH) were measured in 24 children with SCD and normal estimated GFR in a cross sectional study. Correlation and regression analysis were employed to derive relationships between serum phosphorus and several variables.Results: Most children showed elevated age‐ adjusted serum phosphorus (5.1 ± 0.7 mg/dl) levels. Tubular re‐absorption of phosphorus(TRP) (96.3 ± 2.1%) and tubular maximum re‐absorption of phosphorus per unit volume of GFR (TMP/GFR) (4.9 ± 0.6 mg/dl) were both elevated. Plasma intact FGF23 concentrations were elevated (81 ± 38 pg/ml) while the average PTH values were normal in most patients (50 ± 27 pg/ml). Univariate analysis showed significant correlations of serum phosphorus with TMP/GFR, alkaline phosphatase, age, lactate dehydrogenase (LDH), and log intact FGF23. TMP/GFR correlated with log intact FGF23 (r = 0.5, P< or = 0.01) but not with PTH. Multiple regression analysis yielded an independent relationship of serum phosphorus with TMP/GFR.Conclusion: The elevated serum phosphorus concentrations with simultaneously increased TMP/GFR and elevated FGF23 levels collectively suggest that patients with SCD display proximal tubular resistance to the action of FGF23 before any decline in GFR. Pediatr Blood Cancer 2014;61:2267–2270.Keywords
This publication has 31 references indexed in Scilit:
- Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) studyJournal of Bone and Mineral Research, 2013
- Fractional Excretion of Phosphorus Modifies the Association between Fibroblast Growth Factor-23 and OutcomesJournal of the American Society of Nephrology, 2013
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic DialysisJournal of the American Society of Nephrology, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatmentNephrology Dialysis Transplantation, 2010
- FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1American Journal of Physiology-Renal Physiology, 2009
- Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young AdultsJournal of the American Society of Nephrology, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008